High blood pressure, or hypertension, is a major risk factor for heart attacks and strokes. It happens when the force of blood pushing against your artery walls stays too high for too long.

Sparsentan, developed by Travere Therapeutics, is an experimental drug that targets both the endothelin and angiotensin pathways involved in IgAN. The results of the PROTECT study showed that ...

Schlaich said the endothelin pathway has been previously “implicated in the pathogenesis of hypertension,” particularly in sodium and water retention; the endothelin A and B receptors exert their ...

Zibotentan is a novel once daily tablet and works by blocking the endothelin pathway. As prostate cancer advances, this pathway becomes uncontrolled, which then drives the spread of cancer growth.

The first, dual endothelin receptor antagonist aprocitentan, acts by targeting the endothelin pathway implicated in hypertension. It lowered systolic BP after 4 weeks in the phase III, placebo ...

“Since the endothelin pathway was not yet tackled in these patients, we selected aprocitentan, an endothelin receptor antagonist with the ideal properties for use in this condition. We were ...

Hong: Current therapeutic interventions for PAH primarily target three main pathways: the endothelin pathway, the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway and the prostacyclin ...

PER-001 is a first-in-class small molecule in a sustained release proprietary delivery platform that selectively targets inhibition of the endothelin pathway. Endothelin is the most potent ...